Dexcom to Promote COO Jake Leach to CEO

Dexcom announced in its second quarter earnings report that Jake Leach will be promoted to CEO and its Board of Directors, effective January 1, 2026. Current CEO Kevin Sayer will work closely with Leach during the transition and remain executive chairman of the board at the time of transition.

“Today’s announcement of Jake’s transition to the role of chief executive officer reflects the Board’s comprehensive succession planning and their confidence in Jake’s leadership throughout his tenure,” said Sayer. “We are confident that he is the right leader to build on Dexcom’s momentum and extend the company’s growth well into the future.”

Leach has helped pilot the company’s biosensing platforms since the launch of its first commercial system. He’s had roles of rising responsibility in his 21-year stint with the company—he was executive VP and chief technology officer from 2018 through 2022, moving to executive VP and chief operating officer in late 2022.

Leach was promoted to president and chief operating officer in May 2025, adding responsibility of oversight for Dexcom’s strategy and corporate development efforts.

“I am humbled and excited to transition into the CEO role at this critical time in Dexcom’s history,” said Jake Leach. “I look forward to leading our incredible teams as we advance access to our technology to more people around the world, empowering better metabolic health for our customers and creating value for our stakeholders.”